XK-469

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameXK-469
Drug Alias NameNSC-656889XK-469NSC-697887 (free acid)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitors
TargetsTopoisomerase II
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesAnemia, Refractory, with Excess of Blasts +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer InstituteBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBarbara Ann Karmanos Cancer InstituteNational Cancer InstituteBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesAnemia, Refractory, with Excess of Blasts +[18] 

Other Information

ATC CodeN/A
Related LinksN/A